[HAZARDS IN DISCONTINUING GLUCOCORTICOID THERAPY OF ACUTE AND CHRONIC LIVER DISEASES].
D000324:Adrenocorticotropic Hormone; D000410:Alanine Transaminase; D001219:Aspartate Aminotransferases; D004796:Clinical Enzyme Tests; D006505:Hepatitis; D006506:Hepatitis A; D006801:Humans; D007659:Ketones; D008103:Liver Cirrhosis; D008775:Methylprednisolone; D008797:Metyrapone; D000451:Mineralocorticoid Receptor Antagonists; D011241:Prednisone
D007659:Ketones; D000451:Mineralocorticoid Receptor Antagonists; D000324:Adrenocorticotropic Hormone; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D011241:Prednisone; D008775:Methylprednisolone; D008797:Metyrapone
ALANINE AMINOTRANSFERASE; ALDOSTERONE ANTAGONISTS; ASPARTATE AMINOTRANSFERASE; CORTICOTROPIN; ENZYME TESTS; HEPATITIS; KETONES; LIVER CIRRHOSIS; METHYLPREDNISOLONE; METYRAPONE; PREDNISONE
GEFAHREN BEIM ABSETZENDER GLUCOCORTICOIDTHERAPIE AKUTER UND CHRONISCHER LEBERKRANKHEITEN.